Patents by Inventor TATIANA CAÑEQUE

TATIANA CAÑEQUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260008748
    Abstract: The present invention relates to new compounds of formula (I), and their uses.
    Type: Application
    Filed: September 12, 2025
    Publication date: January 8, 2026
    Inventors: TATIANA CAÑEQUE, SEBASTIAN MÜLLER, RAPHAËL RODRIGUEZ
  • Publication number: 20250325516
    Abstract: The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and/or copper-associated disorders.
    Type: Application
    Filed: February 14, 2023
    Publication date: October 23, 2025
    Inventors: RAPHAËL RODRIGUEZ, SEBASTIAN MULLER, TATIANA CAÑEQUE, LUDOVIC COLOMBEAU, LEISHEMBA KHUMAN THOIDINGJAM, FRANCINE CÔTÉ
  • Patent number: 12415781
    Abstract: The present invention relates to new compounds of formula (I), and their uses.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: September 16, 2025
    Assignees: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Tatiana Cañeque, Sebastian Muller, Raphaël Rodriguez
  • Publication number: 20250250280
    Abstract: The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.
    Type: Application
    Filed: September 1, 2022
    Publication date: August 7, 2025
    Inventors: Raphaël RODRIGUEZ, Tatiana CAÑEQUE, Sebastian MÜLLER, Michal ANTOSZCZAK
  • Publication number: 20250250285
    Abstract: The present invention concerns novel specific iron-activable nitrogen-containing derivatives of salinomycin and narasin, their synthesis and their uses in therapy notably for the treatment of cancer. Also disclosed are pharmaceutically acceptable mediums and medicaments for preventing and/or treating cancer, and/or for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.
    Type: Application
    Filed: September 2, 2022
    Publication date: August 7, 2025
    Inventors: Raphaël RODRIGUEZ, Tatiana CAÑEQUE, Sebastian MÜLLER, Michal ANTOSZCZAK
  • Publication number: 20230416196
    Abstract: The present invention relates to compounds comprising two biguanidyl radicals that can be useful as anti-inflammatory agent, and also to new compounds comprising two biguanidyl radicals and their use as a drug, in particular for treating a cancer, a metabolic disease, a secondary mitochondrial disorder due to copper overload including Indian childhood cirrhosis, Wilson's disease and Idiopathic infantile copper toxicosis or due to iron overload, an infection by a virus such as a coronavirus or an influenza virus, a neurodegenerative disease or disorder and aging.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 28, 2023
    Inventors: RAPHAËL RODRIGUEZ, ANTOINE VERSINI, TATIANA CAÑEQUE, SEBASTIAN MÜLLER, STÉPHANIE SOLIER, LEEROY BARON
  • Publication number: 20210230105
    Abstract: The present invention relates to new compounds of formula (I), and their uses.
    Type: Application
    Filed: June 4, 2019
    Publication date: July 29, 2021
    Inventors: TATIANA CAÑEQUE, SEBASTIAN MULLER, RAPHAËL RODRIGUEZ